DeviceSpace.com
Medical Device and Diagnostics
News & Jobs
 
Search the Site
    
 
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login           Employers:  Register | Login  
Medical Device Companies | Diagnostic Companies | Organizations | Search Profiles
 Company Profile

 

Oculus Innovative Sciences, Inc. 

1135 North McDowell Boulevard

Petaluma  California  94954  U.S.A.
Phone: 707-782-0792 Fax: 707-782-0705


SEARCH JOBS

View Clinical Trials from BioPharm Insight

Oculus Innovative Sciences is a biopharmaceutical company that develops, manufactures, and markets a family of Microcyn® Technology-based products intended to help prevent and treat infections in chronic and acute wounds. Oculus’ platform technology, called Microcyn, is a non-irritating proprietary oxychlorine formulation designed to treat a wide range of pathogens, including antibiotic-resistant strains of bacteria, viruses, fungi and spores.

Oculus’ principal operations are in Petaluma, California, and it conducts operations in Europe and Latin America through its wholly-owned subsidiaries, Oculus Innovative Sciences Netherlands B.V. and Oculus Technologies of Mexico, S.A. de C.V.

Last Updated: 05-23-2007

 Key Statistics


Email: hr@oculusis.com
Ownership: Public

Web Site: Oculus Innovative Sciences, Inc.
Employees:
Symbol: OCLS
 









 Company News
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal First Quarter 2015 Financial Results And Conference Call 7/24/2014 10:35:52 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 7/9/2014 9:14:50 AM
Oculus Innovative Sciences, Inc. (OCLS) Reports Revenues Of $2.9 Million And Net Income Of $7.5 Million For Fourth Quarter Of Fiscal 2014 Primarily Due To Accounting Treatment Of Ruthigen IPO Transaction 6/13/2014 8:08:01 AM
Oculus Innovative Sciences, Inc. (OCLS) Sciences Announces Fiscal Fourth Quarter 2014 Financial Results And Conference Call 5/29/2014 8:54:07 AM
Oculus Innovative Sciences, Inc. (OCLS)' Partner, More Pharma Corporation, Launches Microcyn®-Based Oral And Throat Infection Treatment Product In Mexico 4/22/2014 8:54:54 AM
Oculus Innovative Sciences, Inc. (OCLS) Receives "Strong Consensus" Rating For Use With Kinetic Concepts, Inc. (KCI)' Negative Pressure Wound Therapy With Instillation 4/9/2014 8:00:55 AM
Oculus Innovative Sciences, Inc. (OCLS) Shakes Up Board Following Ruthigen IPO 4/2/2014 9:23:36 AM
Oculus Innovative Sciences, Inc. (OCLS) Announces Appointment Of Sharon Barbari To Its Board Of Directors 3/27/2014 9:53:31 AM
Oculus Innovative Sciences, Inc. (OCLS) To Raise $1.35 Million In Registered Direct Offering 2/24/2014 8:59:25 AM
Oculus Innovative Sciences, Inc. (OCLS) Receives Approval For Oral And Throat Infection Products In Mexico 2/19/2014 8:44:22 AM
12345678910...